Squarepoint’s Filana Therapeutics FLNA Stock Holding History

Squarepoint’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-47,000	Closed	-$111K	–	5304
2024 Q4	$111K	Buy	+47,000	New	+$825K	﹤0.01%	4674

Other funds holding FLNA

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Squarepoint's FLNA Position: Q4 2025 in Review

Squarepoint sold out of Filana Therapeutics (FLNA) in Q4 2025, closing a stake of 12,396 shares — an estimated $39.7K sold.

Squarepoint first reported a position in FLNA in Q2 2015 and held it in 14 quarters. The position peaked at $2.33M in Q1 2021. 107 funds tracked by Wall St. Rank hold FLNA as of Q4 2025.

Squarepoint reported no remaining Filana Therapeutics position as of Q4 2025 after selling out during the quarter.
Squarepoint sold 12,396 Filana Therapeutics shares in Q4 2025, an estimated $39.7K.
Squarepoint first reported a position in Filana Therapeutics in Q2 2015 and held it in 14 quarters.
Squarepoint's Filana Therapeutics position peaked at $2.33M in Q1 2021.
107 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.